研究者

J-GLOBAL ID：201801008681809871 更新日: 2022年10月02日

谷口隆志

Takashi Taniguchi

論文 (68件)：

Takashi Yamashita, Yoshihide Asano, Ryosuke Saigusa, Takashi Taniguchi, Kouki Nakamura, Shunsuke Miura, Tetsuo Toyama, Takehiro Takahashi, Yohei Ichimura, Megumi Hirabayashi, et al. Increased expression of aquaporin-1 in dermal fibroblasts and dermal microvascular endothelial cells possibly contributes to skin fibrosis and edema in patients with systemic sclerosis. Journal of dermatological science. 2019. 93. 1. 24-32
Sumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Toyama T, Takahashi T, Ichimura Y, Noda S, Akamata K, et al. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study. The Journal of dermatology. 2018. 45. 12. 1425-1433
Taniguchi T, Miyagawa T, Toyama S, Yamashita T, Nakamura K, Saigusa R, Ichimura Y, Takahashi T, Toyama T, Yoshizaki A, et al. CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis. Experimental dermatology. 2018. 27. 9. 1030-1037
Miyagawa T, Ichimura Y, Nakamura K, Hirabayashi M, Yamashita T, Saigusa R, Miura S, Takahashi T, Toyama T, Taniguchi T, et al. Progranulin overproduction due to constitutively activated c-Abl/PKC-δ/Fli1 pathway contributes to the resistance of dermal fibroblasts to the anti-fibrotic effect of tumor necrosis factor-α in localized scleroderma. Journal of dermatological science. 2018. 92. 2. 207-214
Yamashita T, Lakota K, Taniguchi T, Yoshizaki A, Sato S, Hong W, Zhou X, Sodin-Semrl S, Fang F, Asano Y, et al. An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis. Scientific reports. 2018. 8. 1. 11843

もっと見る

学位 (1件)：

医学博士 (東京大学大学院医学系研究科)

経歴 (1件)：

国際医療福祉大学医学部皮膚科講師

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

前のページに戻る

TOP

BOTTOM